Sort
17,828 grants matching “crispr”
Innate Immune Control of TB and HIV
$646,050Anne Goldfeld · Boston Children'S Hospital · R56 · FY2021 · AI
Reverse Engineering of Cell Senescence
$646,046Marc W Kirschner · Harvard Medical School · R01 · FY2025 · AG
Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomics
$646,006Martin Kampmann · University Of California, San Francisco · R01 · FY2020 · AG
Activation and Inhibition Mechanisms of Calcium-Activated Nonselective Cation Channels
$645,836Jie Zheng · University Of California At Davis · R01 · FY2023 · NS
Next-generation Drosophila cell lines to elucidate the cellular basis of human diseases
$645,802Norbert Perrimon · Harvard Medical School · R24 · FY2020 · OD
Defining Strategies to Target Energy Failure in Metabolically Vulnerable Human Cells
$645,796Ken Nakamura · J. David Gladstone Institutes · R01 · FY2023 · AG
Defining Strategies to Target Energy Failure in Metabolically Vulnerable Human Cells
$645,796Ken Nakamura · J. David Gladstone Institutes · R01 · FY2022 · AG
Defining Strategies to Target Energy Failure in Metabolically Vulnerable Human Cells
$645,796Ken Nakamura · J. David Gladstone Institutes · R01 · FY2021 · AG
In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies
$645,746James Even Voss · Scripps Research Institute, The · R01 · FY2022 · AI
BMPR2, Monocytes and Macrophages in Pulmonary Artery Hypertension
$645,730Marlene Rabinovitch · Stanford University · R01 · FY2025 · HL
Gene regulatory networks in early lung epithelial cell fate decisions
$645,689Laertis Ikonomou · State University Of New York At Buffalo · R01 · FY2023 · HL
Interplay of M. tuberculosis trehalose metabolism and its pathogenesis and drug resistance
$645,686Hyungjin Eoh · University Of Southern California · R01 · FY2025 · AI
Interplay of M. tuberculosis trehalose metabolism and its pathogenesis and drug resistance
$645,686Hyungjin Eoh · University Of Southern California · R01 · FY2024 · AI
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** CITRUS IS ONE OF THE MOST IMPORTANT FRUIT CROPS IN THE U.S. AND IN THE WORLD WITH MANY CULTIVATED VARIETIES. THE PRODUCTION OF CITRUS IN THE U.S. HAS BEEN DEVASTED BY THE BACTERIAL DISEASES HUANGLONGBING (HLB), AND TO SOME EXTENT BY CITRUS CANKER. WE HAVE GENERATED MULTIPLE CITRUS GENOME-EDITED LINES TARGETING SIX SELECTED HOST PLANT SUSCEPTIBILITY (S) GENES TO ACHIEVE RESISTANCE AGAINST THESE DEVASTATING BACTERIAL DISEASES. BECAUSE COMMERCIAL CITRUS HAS TO BE CLONALLY PROPAGATED, GENE-EDITED CITRUS PLANTS WILL HAVE STABLY INCORPORATED CRISPR REAGENTS IN THEIR GENOMES THROUGH GENERATIONS. THIS INDICATES THAT THERE IS A POSSIBILITY OF CONTINUED CRISPR ACTIVITY AFFECTING BOTH GENOTYPE AND PHENOTYPE OF GENE-EDITED CITRUS LINES. THEREFORE, RISK-ASSESSMENT OF GENE-EDITING TECHNOLOGY FOR ENGINEERING CITRUS SPECIES IS IMPERATIVE TO MEET THE URGENT NEED FROM THE U.S. CITRUS INDUSTRY. WE PROPOSE TO PERFORM COMPREHENSIVE EVALUATION OF GENOME-WIDE OFF TARGET EFFECTS AND ASSOCIATED PHENOTYPES IN THESE CITRUS GENE-EDITED LINES COMPARED TO NON-MODIFIED CONTROLS IN FIELD STUDIES. FURTHER, WE WILL ALSO EVALUATE THE STABILITY OF EDITS AND PHENOTYPES OVER MULTIPLE YEARS UNDER FIELD CONDITIONS. THE RESULTS FROM THIS PROJECT WILL PROVIDE CITRUS GERMPLASM TO COMBAT BACTERIAL DISEASES AND ASSIST REGULATORY AGENCIES TO EFFECTIVELY AND COMPREHENSIVELY ASSESS THE RISKS OF GENE-EDITING IN CITRUS AT BOTH GENOTYPIC AND PHENOTYPIC LEVELS.
$645,674University Of Florida · · FY2024 · National Institute of Food and Agriculture
Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparities
$645,565Matthew J Sikora · University Of Colorado Denver · R01 · FY2023 · CA
Characterizing Human RPE Cell Proliferation to Advance Endogenous Regeneration
$645,471Sally Temple · Regenerative Research Foundation · R01 · FY2021 · EY
Mechanistic Insight to Predict and Prevent Nilotinib-Induced Artery Disease
$645,460Paul W. Burridge · Northwestern University At Chicago · R01 · FY2025 · CA
Perturbations of host cell signaling by a complex hepatotropic pathogen
$645,448Alexis Kaushansky · Seattle Children'S Hospital · R01 · FY2024 · AI
A novel mechanism of virulence control in Porphyromonas gingivalis
$645,439Jorge Frias-Lopez · University Of Florida · R01 · FY2024 · DE
Generation of a Complete Set of Precise Null Bar-Coded Deletion Mutants of Mycobacterium tuberculosis
$645,418William Robert Jacobs · Albert Einstein College Of Medicine · R24 · FY2025 · AI
Genetic Repair of Familial Hypercholesterolemia
$645,390William Raymond Lagor · Baylor College Of Medicine · R01 · FY2019 · HL
Genetic Repair of Familial Hypercholesterolemia
$645,390William Raymond Lagor · Baylor College Of Medicine · R01 · FY2021 · HL
Genetic Repair of Familial Hypercholesterolemia
$645,390William Raymond Lagor · Baylor College Of Medicine · R01 · FY2020 · HL
CRISPR-enhanced adipocyte browning to improve glucose tolerance in obesity and diabetes
$645,361Michael P Czech · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · DK
Bile acid-mediated control of lipid absorption and fatty liver disease
$645,340Thomas A Vallim · University Of California Los Angeles · R01 · FY2025 · DK